Does the media prefer TVTX or ASND?

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 3 mentions for Travere Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.41 beat Travere Therapeutics' score of 0.61 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TVTX or RGC?

Travere Therapeutics presently has a consensus target price of $47.83, suggesting a potential upside of 0.15%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Travere Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, TVTX or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Travere Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Travere Therapeutics $490.73M 9.05 -$25.55M -$0.23 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media prefer TVTX or RGC?

In the previous week, Regencell Bioscience had 14 more articles in the media than Travere Therapeutics. MarketBeat recorded 17 mentions for Regencell Bioscience and 3 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.61 beat Regencell Bioscience's score of 0.12 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BBIO or TVTX?

In the previous week, BridgeBio Pharma had 20 more articles in the media than Travere Therapeutics. MarketBeat recorded 23 mentions for BridgeBio Pharma and 3 mentions for Travere Therapeutics. BridgeBio Pharma's average media sentiment score of 0.70 beat Travere Therapeutics' score of 0.61 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TVTX or SMMT?

In the previous week, Summit Therapeutics had 2 more articles in the media than Travere Therapeutics. MarketBeat recorded 5 mentions for Summit Therapeutics and 3 mentions for Travere Therapeutics. Summit Therapeutics' average media sentiment score of 0.93 beat Travere Therapeutics' score of 0.61 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AXSM or TVTX?

In the previous week, Axsome Therapeutics had 6 more articles in the media than Travere Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 3 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.61 beat Axsome Therapeutics' score of 0.60 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Travere Therapeutics (TVTX) Competitors

$47.76 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$47.78 +0.02 (+0.03%)

As of 06:37 PM Eastern

Compare

TVTX vs. ASND, RGC, BBIO, SMMT, and AXSM

Should you buy Travere Therapeutics stock or one of its competitors? MarketBeat compares Travere Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Travere Therapeutics include Ascendis Pharma A/S (ASND), Regencell Bioscience (RGC), BridgeBio Pharma (BBIO), Summit Therapeutics (SMMT), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Travere Therapeutics (NASDAQ:TVTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Ascendis Pharma A/S has a net margin of 57.87% compared to Travere Therapeutics' net margin of -4.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Travere Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Travere Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	9.05	-$25.55M	-$0.23	N/A
Ascendis Pharma A/S	$814.57M	18.19	-$258M	$8.67	27.39

Travere Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Travere Therapeutics presently has a consensus price target of $47.83, indicating a potential upside of 0.15%. Ascendis Pharma A/S has a consensus price target of $295.39, indicating a potential upside of 24.39%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 3 mentions for Travere Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.41 beat Travere Therapeutics' score of 0.61 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Travere Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Travere Therapeutics compare to Regencell Bioscience?

Travere Therapeutics (NASDAQ:TVTX) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

In the previous week, Regencell Bioscience had 14 more articles in the media than Travere Therapeutics. MarketBeat recorded 17 mentions for Regencell Bioscience and 3 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.61 beat Regencell Bioscience's score of 0.12 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Regencell Bioscience has lower revenue, but higher earnings than Travere Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	9.05	-$25.55M	-$0.23	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Regencell Bioscience has a net margin of 0.00% compared to Travere Therapeutics' net margin of -4.00%. Regencell Bioscience's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Regencell Bioscience	N/A	N/A	N/A

Travere Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Travere Therapeutics presently has a consensus target price of $47.83, suggesting a potential upside of 0.15%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Travere Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Regencell Bioscience beats Travere Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Travere Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

BridgeBio Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

BridgeBio Pharma currently has a consensus target price of $88.90, indicating a potential upside of 29.88%. Travere Therapeutics has a consensus target price of $47.83, indicating a potential upside of 0.15%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe BridgeBio Pharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

99.9% of BridgeBio Pharma shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 20 more articles in the media than Travere Therapeutics. MarketBeat recorded 23 mentions for BridgeBio Pharma and 3 mentions for Travere Therapeutics. BridgeBio Pharma's average media sentiment score of 0.70 beat Travere Therapeutics' score of 0.61 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	10 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Travere Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.70	-$724.93M	-$3.74	N/A
Travere Therapeutics	$490.73M	9.05	-$25.55M	-$0.23	N/A

Travere Therapeutics has a net margin of -4.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Summary

BridgeBio Pharma beats Travere Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to Summit Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

4.6% of Summit Therapeutics shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Summit Therapeutics had 2 more articles in the media than Travere Therapeutics. MarketBeat recorded 5 mentions for Summit Therapeutics and 3 mentions for Travere Therapeutics. Summit Therapeutics' average media sentiment score of 0.93 beat Travere Therapeutics' score of 0.61 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics presently has a consensus price target of $47.83, suggesting a potential upside of 0.15%. Summit Therapeutics has a consensus price target of $26.05, suggesting a potential upside of 49.65%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summit Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -4.00%. Travere Therapeutics' return on equity of -26.16% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Summit Therapeutics	N/A	-291.24%	-243.07%

Travere Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.25, meaning that its share price is 225% less volatile than the broader market.

Travere Therapeutics has higher revenue and earnings than Summit Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	9.05	-$25.55M	-$0.23	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Summary

Travere Therapeutics and Summit Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Axsome Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Axsome Therapeutics presently has a consensus price target of $251.26, suggesting a potential upside of 7.92%. Travere Therapeutics has a consensus price target of $47.83, suggesting a potential upside of 0.15%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Axsome Therapeutics had 6 more articles in the media than Travere Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 3 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.61 beat Axsome Therapeutics' score of 0.60 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Travere Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.76	-$183.17M	-$3.73	N/A
Travere Therapeutics	$490.73M	9.05	-$25.55M	-$0.23	N/A

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Travere Therapeutics has a net margin of -4.00% compared to Axsome Therapeutics' net margin of -26.59%. Travere Therapeutics' return on equity of -26.16% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Summary

Axsome Therapeutics beats Travere Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Travere Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVTX vs. The Competition

Export

Metric	Travere Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.44B	$3.40B	$6.44B	$12.57B
Dividend Yield	N/A	2.27%	2.75%	5.25%
P/E Ratio	-207.64	18.98	21.55	26.15
Price / Sales	9.05	344.00	618.79	118.48
Price / Cash	122.30	122.89	43.13	56.80
Price / Book	45.06	7.16	10.53	7.26
Net Income	-$25.55M	$24.20M	$3.56B	$337.24M
7 Day Performance	6.75%	3.96%	3.21%	3.91%
1 Month Performance	16.80%	5.98%	4.59%	5.84%
1 Year Performance	219.46%	66.45%	37.82%	38.37%

Travere Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVTX Travere Therapeutics	1.4024 of 5 stars	$47.76 flat	$47.83 +0.2%	+211.3%	$4.44B	$490.73M	N/A	460
ASND Ascendis Pharma A/S	4.5609 of 5 stars	$236.60 -1.6%	$291.78 +23.3%	+49.6%	$14.76B	$814.57M	27.29	1,189	Positive News Short Interest Decrease
RGC Regencell Bioscience	0.1696 of 5 stars	$28.28 -1.1%	N/A	N/A	$13.98B	N/A	N/A	10	Trending News
BBIO BridgeBio Pharma	3.5503 of 5 stars	$64.42 -2.6%	$88.19 +36.9%	+100.7%	$12.62B	$502.08M	N/A	400	Analyst Downgrade Insider Trade
SMMT Summit Therapeutics	2.503 of 5 stars	$15.99 -5.2%	$27.58 +72.5%	-32.3%	$12.41B	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVTX) was last updated on 5/28/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (TVTX) Competitors

TVTX vs. ASND, RGC, BBIO, SMMT, and AXSM

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Travere Therapeutics compare to Regencell Bioscience?

Summary

How does Travere Therapeutics compare to BridgeBio Pharma?

Summary

How does Travere Therapeutics compare to Summit Therapeutics?

Summary

How does Travere Therapeutics compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Travere Therapeutics (TVTX) Competitors

TVTX vs. ASND, RGC, BBIO, SMMT, and AXSM

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Is TVTX or ASND more profitable?

Which has higher valuation and earnings, TVTX or ASND?

Which has more risk & volatility, TVTX or ASND?

Do analysts rate TVTX or ASND?

Does the media prefer TVTX or ASND?

Summary

How does Travere Therapeutics compare to Regencell Bioscience?

Does the media prefer TVTX or RGC?

Which has stronger earnings & valuation, TVTX or RGC?

Is TVTX or RGC more profitable?

Which has more volatility and risk, TVTX or RGC?

Do institutionals & insiders hold more shares of TVTX or RGC?

Do analysts recommend TVTX or RGC?

Summary

How does Travere Therapeutics compare to BridgeBio Pharma?

Which has more volatility and risk, BBIO or TVTX?

Do analysts rate BBIO or TVTX?

Do insiders and institutionals believe in BBIO or TVTX?

Does the media refer more to BBIO or TVTX?

Which has preferable valuation & earnings, BBIO or TVTX?

Is BBIO or TVTX more profitable?

Summary

How does Travere Therapeutics compare to Summit Therapeutics?

Do insiders & institutionals hold more shares of TVTX or SMMT?

Does the media prefer TVTX or SMMT?

Do analysts rate TVTX or SMMT?

Is TVTX or SMMT more profitable?

Which has more volatility & risk, TVTX or SMMT?

Which has preferable valuation & earnings, TVTX or SMMT?

Summary

How does Travere Therapeutics compare to Axsome Therapeutics?

Which has more volatility & risk, AXSM or TVTX?

Do analysts recommend AXSM or TVTX?

Does the media favor AXSM or TVTX?

Which has better valuation and earnings, AXSM or TVTX?

Do insiders and institutionals have more ownership in AXSM or TVTX?

Is AXSM or TVTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools